- Published
- 06 September 2024
- Journal article
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
- Authors
-
- Source
- The Lancet Diabetes & Endocrinology
Abstract
Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been proposed as a potential treatment for 3 adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective 4 effects. To-date published evidence from randomised control trials (RCTs) does not provide evidence 5 of benefit. We aimed to estimate the effect of oral administration of SGLT2i compared with usual care 6 or placebo in adults hospitalised with COVID-19.
Rights
This is an open access article distributed under the terms of the Creative Commons CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
Cite as
Vale, C., Godolphin, P., Fisher, D., Horby, P., Kosiborod, M., Hochman, J., Webster, K., Higgins, J., Althouse, A., Berwanger, O., Furtado, R., Gasparyan, S., Haynes, R., Koch, G., Landray, M., Leifer, E., Marshall, J., Murthy, S., Neal, M., Staplin, N., Diaz, J., Sterne, J. & Shankar-Hari, M. 2024, 'Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials', The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(24)00219-5